

Renal Cell Carcinoma: Identification and Management

Resource	Address
Brahmer JR, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol</i> . 2018;36:1714-1768.	https://pubmed.ncbi.nlm.nih.gov/29442540/
Cao G, et al. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. <i>BMJ Open</i> . 2020;10:e034626.	https://pubmed.ncbi.nlm.nih.gov/32859659/
Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. <i>Immunity</i> . 2013;39:1-10.	https://pubmed.ncbi.nlm.nih.gov/23890059/
Choueiri TK, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. <i>NEJM</i> . 2021;384:829-841.	https://pubmed.ncbi.nlm.nih.gov/33657295/
Heng DYC, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. <i>Lancet Oncol</i> . 2013;14:141-148.	https://pubmed.ncbi.nlm.nih.gov/23312463/
Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. <i>Nat Rev Clin Oncol</i> . 2019;16:621-633.	https://pubmed.ncbi.nlm.nih.gov/30992569/
Michot JM, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. <i>Eur J Cancer</i> . 2016;54:139-148.	https://pubmed.ncbi.nlm.nih.gov/26765102/
Osawa T, et al. Overview of current and future systemic therapy for metastatic renal cell carcinoma. <i>Jpn J Clin Oncol</i> . 2019;49:395-403.	https://pubmed.ncbi.nlm.nih.gov/30722031/
Motzer RJ, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. <i>N Engl J Med</i> . 2019;380:1103-1115.	https://pubmed.ncbi.nlm.nih.gov/30779531/
Palapattu GS, et al. Paraneoplastic syndromes in urologic malignancy: The many faces of renal cell carcinoma. <i>Rev Urol</i> . 2002;4:163-170.	https://pubmed.ncbi.nlm.nih.gov/16985675/

Puzanov I, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. <i>J Immunother Cancer</i> . 2017;5:95.	https://pubmed.ncbi.nlm.nih.gov/29162153/
Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. <i>N Engl J Med</i> . 2019;380:1116-1127.	https://www.nejm.org/doi/full/10.1056/NEJMoa1816714
Sanchez-Gastaldo A, et al. Systemic treatment of renal cell cancer: A comprehensive review. <i>Cancer Treat Rev</i> . 2017;60:77-89.	https://pubmed.ncbi.nlm.nih.gov/28898679/
Weber JS, et al. Toxicities of immunotherapy for the practitioner. <i>J Clin Oncol</i> . 2015;33:2092-2099.	https://pubmed.ncbi.nlm.nih.gov/25918278/
Zerdes I, et al. Systemic therapy of metastatic renal cell carcinoma: Review of the current literature. <i>Urologia</i> . 2019;86:3-8.	https://pubmed.ncbi.nlm.nih.gov/30270773/

Resources and Societies

Resource	Address
American Association for Cancer Research (AACR). Accessed April 8, 2021.	https://www.aacr.org/
American Cancer Society (ACS). Kidney Cancer. Accessed April 8, 2021.	https://www.cancer.org/cancer/kidney-cancer.html
American Society of Clinical Oncology (ASCO). Accessed April 8, 2021.	https://www.asco.org/
European Society for Medical Oncology (ESMO). Accessed April 8, 2021.	https://www.esmo.org/
Kidney Cancer Association. Accessed April 8, 2021.	https://www.kidneycancer.org/
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 3.2021. Published March 23, 2021. Accessed April 8, 2021.	https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf